We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 2.2%.
The Zacks Consensus Estimate for revenues is pinned at $4.4 billion, implying 6.4% year-over-year growth.
The Research & Development Solutions (RD&S) segment is expected to have improved on the back of improving demand for outsourced clinical research services, higher request-for-proposal activity and briefer client decision timelines.
The consensus estimate for bookings is pinned at $34.67 billion, marking 7% year-over-year growth. Solid bookings growth is expected to have provided revenue visibility, providing support to the top line.
Advancing funding conditions for emerging biopharma companies are anticipated to have stimulated clinical trial activity and outsourcing demand. Strength across the RD&S segment is expected to have improved on the back of renewed outsourcing agreements, increased preferred-provider relationships and higher win rates among large pharma companies.
IQVIA is likely to have experienced improvement in its information services, analytics, consulting, patient solutions and commercial engagement businesses from higher commercialization spending.
Rapid AI adoption is expected to emerge as a vital growth driver. Growing utilization of the company’s AI capabilities across clinical trial management, patient recruitment, drug launch planning and commercial analytics is expected to have solidified customer engagement and generate incremental revenues.
The consensus estimate for earnings per share is $3.24, marking an 8% year-over-year growth. Continued execution of operational efficiency initiatives is expected to have supported profitability. Swift adoption of AI-driven automation is anticipated to have lowered operational costs, further improving operational prowess.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.09% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Beta Bionics (BBNX - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $35.2 million, indicating 29.1% year-over-year growth. The consensus mark for loss is pinned at 53 cents per share, whereas it incurred a loss of 33 cents in the year-ago quarter. The company beat the consensus estimate in all four quarters, with an average surprise of 19.3%.
The company is scheduled to declare third-quarter 2026 results on Oct. 27.
Elanco Animal Health (ELAN - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pinned at $1.2 billion, hinting at 6.1% year-over-year growth. For earnings, the consensus mark is pinned at 20 cents per share, improving 5.3% from the year-ago quarter’s reported figure. ELAN beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 27%.
ELAN has an Earnings ESP of +3.70% and a Zacks Rank of 2 at present.The company is scheduled to declare third-quarter 2026 results on Nov. 6.
View the Zacks #1 Rank List
Image: Bigstock
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
Key Takeaways
IQVIA Holdings (IQV - Free Report) is set to release third-quarter 2026 results on Oct. 27, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 2.2%.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
IQVIA’s Q3 Expectations
The Zacks Consensus Estimate for revenues is pinned at $4.4 billion, implying 6.4% year-over-year growth.
The Research & Development Solutions (RD&S) segment is expected to have improved on the back of improving demand for outsourced clinical research services, higher request-for-proposal activity and briefer client decision timelines.
The consensus estimate for bookings is pinned at $34.67 billion, marking 7% year-over-year growth. Solid bookings growth is expected to have provided revenue visibility, providing support to the top line.
Advancing funding conditions for emerging biopharma companies are anticipated to have stimulated clinical trial activity and outsourcing demand. Strength across the RD&S segment is expected to have improved on the back of renewed outsourcing agreements, increased preferred-provider relationships and higher win rates among large pharma companies.
IQVIA is likely to have experienced improvement in its information services, analytics, consulting, patient solutions and commercial engagement businesses from higher commercialization spending.
Rapid AI adoption is expected to emerge as a vital growth driver. Growing utilization of the company’s AI capabilities across clinical trial management, patient recruitment, drug launch planning and commercial analytics is expected to have solidified customer engagement and generate incremental revenues.
The consensus estimate for earnings per share is $3.24, marking an 8% year-over-year growth. Continued execution of operational efficiency initiatives is expected to have supported profitability. Swift adoption of AI-driven automation is anticipated to have lowered operational costs, further improving operational prowess.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.09% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Beta Bionics (BBNX - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $35.2 million, indicating 29.1% year-over-year growth. The consensus mark for loss is pinned at 53 cents per share, whereas it incurred a loss of 33 cents in the year-ago quarter. The company beat the consensus estimate in all four quarters, with an average surprise of 19.3%.
BBNX carries an Earnings ESP of +3.77% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is scheduled to declare third-quarter 2026 results on Oct. 27.
Elanco Animal Health (ELAN - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pinned at $1.2 billion, hinting at 6.1% year-over-year growth. For earnings, the consensus mark is pinned at 20 cents per share, improving 5.3% from the year-ago quarter’s reported figure. ELAN beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 27%.
ELAN has an Earnings ESP of +3.70% and a Zacks Rank of 2 at present.The company is scheduled to declare third-quarter 2026 results on Nov. 6.